
Guide for the Assessment of Clotting Factor Concentrates
The purpose of this guide is to inform and facilitate the selection and purchase of therapeutic products for the treatment
Year: 2016
Language: English
This resource is also available in: Arabic French Russian Spanish Simplified Chinese
Author(s): World Federation of Hemophilia
Format: Document
This resource has also been translated into the following languages, with permission from the WFH, by NMOs: Polish
Desmopressin (DDAVP) may be the treatment of choice for patients with mild or moderate hemophilia A and type 1 von Willebrand disease (VWD). This Fact Sheet presents essential information about this synthetic medicine which costs much less than plasma products or recombinant clotting factor concentrates, carries no risk of transmission of viral infections, and is on the World Health Organization’s (WHO) Model List of Essential Medicines (EML).

The purpose of this guide is to inform and facilitate the selection and purchase of therapeutic products for the treatment

A summary of discussions held at the Tenth WFH Global Forum on Research and Treatment Products for Bleeding Disorders which

This illustrated schematic demonstrates the normal process of blood clotting, how it is diminished when a clotting factor is lacking,

In the Tuesday morning medical plenary, Erik Berntorp describes his vision of hemophilia treatment and medical advances in 2030.

This eLearning module presents Section 4 of the WFH Guidelines for the Management of Hemophilia: Hemostatic Agents. Detailed illustrations, interactive